# Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

> **NCT00411905** · PHASE1,PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 45 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00411905
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-01
- **Primary completion:** 2010-07-08
- **Final completion:** 2011-08-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411905, "Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00411905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*